A phase I/II clinical trial of CM518D1 in solid tumors
Latest Information Update: 11 Apr 2025
At a glance
- Drugs CM 518D1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 11 Apr 2025 New trial record
- 26 Mar 2025 According to a Keymed Biosciences media release, company submitted IND application to CDE, and planned to conduct a phase 1/2 clinical study in advanced solid tumors.